-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.
-
Summary
-
SAB Biotherapeutics, Inc. quarterly/annual Depreciation, Depletion and Amortization history and growth rate from Q1 2021 to Q3 2024.
- SAB Biotherapeutics, Inc. Depreciation, Depletion and Amortization for the quarter ending September 30, 2024 was $900K, a 10% decline year-over-year.
- SAB Biotherapeutics, Inc. Depreciation, Depletion and Amortization for the twelve months ending September 30, 2024 was $4.72M, a 27.8% increase year-over-year.
- SAB Biotherapeutics, Inc. annual Depreciation, Depletion and Amortization for 2023 was $3.65M, a 15.3% increase from 2022.
- SAB Biotherapeutics, Inc. annual Depreciation, Depletion and Amortization for 2022 was $3.17M, a 113% increase from 2021.
- SAB Biotherapeutics, Inc. annual Depreciation, Depletion and Amortization for 2021 was $1.49M, a 289% increase from 2020.
Depreciation, Depletion and Amortization, Trailing 12 Months (USD)
Depreciation, Depletion and Amortization, Quarterly (USD)
Depreciation, Depletion and Amortization, YoY Quarterly Growth (%)